Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
Singapore, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (NASDAQ:BMGL) (the "Company"), today announced that it has received notification from Nasdaq that based on the closing bid price of the Company's shares for the last 30 consecutive business days, the Company no longer meets the requirements under Nasdaq's Listing Rules (the "Rules") for listed securities to maintain a minimum bid price of $1 per share. The Rules provide the Company a compliance period of 180 calendar days in which to regain compliance. If at any time during this 180 day period the closing bid price of the Company's security is at least $1 for a minimum of ten consecutive business days, Nasdaq will provid
Singapore, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (NASDAQ:BMGL) (the "Company"), today announced that it has received notification from Nasdaq that the Company's annual report on Form 20-F for the fiscal year ended June 30, 2025 was incomplete and that the Company is delinquent in its filing obligations. This was because such report failed to include an opinion from the Company's auditor, NLA DFK Assurance PAC, on the Company's financial statements. Pursuant to Listing Rule 5250(c)(1), companies shall timely file all required periodic financial reports with the United States Securities and Exchange Commission, and annual reports filed shall contain audited financial stat
Singapore, July 17, 2025 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (NASDAQ:BMGL), today announced that it is putting on hold on the acquisition of BTC digital asset. After thorough discussions, Basel and the consortium of Bitcoin (BTC) holders have mutually agreed to pause the acquisition of digital asset. This decision reflects the ongoing regulatory review of digital assets by US authorities and the current lack of clarity on how forthcoming policies may impact the transaction. Given these uncertainties, both parties believe it is prudent to defer the deal until there is greater regulatory certainty. We will continue to monitor developments closely and reassess the opportunity once th
3 - Basel Medical Group Ltd (0002004489) (Issuer)
20-F/A - Basel Medical Group Ltd (0002004489) (Filer)
6-K - Basel Medical Group Ltd (0002004489) (Filer)
6-K - Basel Medical Group Ltd (0002004489) (Filer)